Silk Road Medical (SILK) Stock Price, News & Analysis

Company Overview

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Key Stats

• Today's Range: $27.49 to $27.49
• 50-Day Range: $27.01 to $27.50
• 52-Week Range: $6.08 to $27.51
• Volume: N/A
• Average Volume: 1.20 million shs
• Market Capitalization: $1.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Reduce

Silk Road Medical Stock Analysis - MarketRank™

Silk Road Medical scored higher than 9% of companies evaluated by MarketBeat, and ranked 948th out of 971 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Silk Road Medical has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Silk Road Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Silk Road Medical are expected to grow in the coming year, from ($1.45) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Silk Road Medical is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silk Road Medical is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silk Road Medical has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SILK.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silk Road Medical does not currently pay a dividend.

Dividend Growth

Silk Road Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.74

Short Interest

There is no current short interest data available for SILK.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Silk Road Medical this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Silk Road Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $61,463.00 in company stock.

Percentage Held by Insiders

Only 3.90% of the stock of Silk Road Medical is held by insiders.

SILK Stock Analysis - Frequently Asked Questions

How were Silk Road Medical's earnings last quarter?

Silk Road Medical, Inc (NASDAQ:SILK) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.04. The business's revenue for the quarter was up 13.0% compared to the same quarter last year.

When did Silk Road Medical IPO?

Silk Road Medical (SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Who are Silk Road Medical's major shareholders?

Silk Road Medical's top institutional investors include Walleye Capital LLC and Crawford Fund Management LLC. Insiders that own company stock include Lucas W Buchanan, Andrew S Davis, Erica J Rogers, Kevin M Klemz, Richard Ruedy, Marie L Jones and Tony M Chou.
View institutional ownership trends.

What other stocks do shareholders of Silk Road Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silk Road Medical investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SILK
• CUSIP: N/A
• CIK: 1397702
• Web: www.silkroadmed.com
• Phone: (408) 720-9002
• Fax: 408-720-9013
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $27.50
• Low Stock Price Target: $20.00
• Potential Upside/Downside: -12.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-55,740,000.00
• Net Margins: -29.53%
• Pretax Margin: -29.53%
• Return on Equity: -37.30%
• Return on Assets: -21.57%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 7.63
• Quick Ratio: 6.69

Sales & Book Value

• Annual Sales: $177.13 million
• Price / Sales: 6.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.88 per share
• Price / Book: 7.09

Miscellaneous

• Outstanding Shares: 40,630,000
• Free Float: 37,906,000
• Market Cap: $1.12 billion
• Optionable: Optionable
• Beta: 1.53